A new pharmacological molecule improves the safety of canine sedation and anaesthesia

October 31, 2018, University of Helsinki
Credit: CC0 Public Domain

A drug discovery made at the University of Helsinki's Faculty of Veterinary Medicine will increase the safety of animal sedation and anaesthesia. Vatinoxan, the pharmacological molecule discovered in the study, reduced the adverse effects of other drugs on the cardiovascular system of canine patients.

The research project leading to the discovery was launched more than a decade ago when veterinary researchers were investigating the of sedatives and anaesthetics on animal patients. They developed the idea to prevent or at least reduce the disadvantages associated with anaesthetics through the use of drugs, and the new research line generated in the process has led to the submission of two .

Now, the efficacy and safety of the new drug has been for the first time trialled on canine patients at the Veterinary Teaching Hospital of the University of Helsinki.

"As veterinary drug studies take time and money, it is a great achievement that we have succeeded in advancing vatinoxan's development to the point where it has been possible to trial it on volunteered canine patients," says Outi Vainio, professor of veterinary pharmacology and head of the project.

"It has been rewarding to observe that the new drug really works on the canine patients as expected," notes Ira Kallio-Kujala, a doctoral student and veterinarian working at the Veterinary Teaching Hospital who served as the project's principal investigator.

The drug is aimed for marketing authorisation within a couple of years.

Explore further: New clinical trials seek treatments for canine cancers, may offer clues on human cancers

More information: I.J. Kallio-Kujala et al. Peripherally acting α-adrenoceptor antagonist MK-467 with intramuscular medetomidine and butorphanol in dogs: A prospective, randomised, clinical trial, The Veterinary Journal (2018). DOI: 10.1016/j.tvjl.2018.08.007

Related Stories

New approach to treating chronic itch

August 15, 2018

Researchers at the University of Zurich have discovered a new approach to suppressing itch by targeting two receptors in the spinal cord with the right experimental drug. In a series of experiments in mice and dogs, they ...

Promising new drug development could treat cachexia

April 18, 2017

According to the National Cancer Institute, nearly one-third of cancer deaths can be attributed to a wasting syndrome known as cachexia. Cachexia, an indicator of the advanced stages of disease, is a debilitating disorder ...

Recommended for you

EPA adviser is promoting harmful ideas, scientists say

March 22, 2019

The Trump administration's reliance on industry-funded environmental specialists is again coming under fire, this time by researchers who say that Louis Anthony "Tony" Cox Jr., who leads a key Environmental Protection Agency ...

Coffee-based colloids for direct solar absorption

March 22, 2019

Solar energy is one of the most promising resources to help reduce fossil fuel consumption and mitigate greenhouse gas emissions to power a sustainable future. Devices presently in use to convert solar energy into thermal ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.